Search - tctmd.com

Displaying 1 - 20 of 68

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

News Conference News SCAI 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

May 07, 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

March 14, 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

March 09, 2024

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

October 31, 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

June 21, 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

June 09, 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

May 31, 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

May 22, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.